Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia 8Leukemia, Myeloid, Chronic-Phase 6Blast Crisis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Sarcoma 4Melanoma 4Gastrointestinal Stromal Tumors 4Leukemia, Myeloid, Accelerated Phase 3Sarcoma, Synovial 2Oligodendroglioma 2Leukemia, Myeloid, Acute 2Glioma 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2Brain Neoplasms 2Astrocytoma 2Uterine Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Refractory Desmoplastic Small Round Cell Tumors 1Prostatic Neoplasms 1Primary Myelofibrosis 1Piebaldism 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neurofibromatoses 1

Interventions

vandetanib 3selpercatinib 2rovalpituzumab tesirine 1pralsetinib 1Peripheral Blood Stem Cell Transplantation 1Indium 1Imatinib Mesylate 1Filgrastim 1Doxorubicin 1Dexamethasone 1Dacarbazine 1Capecitabine 1Calcium Aluminosilicate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Medullary × Imatinib Mesylate × Clear all
NCT00354523 2014-12-17

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
21 enrolled
Head & Neck

Thyroid Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡